Mark Elliott Boulding - Sep 20, 2022 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
EXEC. VP AND CLO
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Stock symbol
PTCT
Transactions as of
Sep 20, 2022
Transactions value $
-$64,680
Form type
4
Date filed
9/22/2022, 04:38 PM
Previous filing
Apr 15, 2022
Next filing
Oct 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Options Exercise $27K +876 +1.43% $30.86 62K Sep 20, 2022 Direct F1
transaction PTCT Common Stock Sale -$48.2K -876 -1.41% $55.00 61.1K Sep 20, 2022 Direct F1
transaction PTCT Common Stock Options Exercise $9.26K +300 +0.49% $30.86 61.4K Sep 20, 2022 Direct F1
transaction PTCT Common Stock Sale -$16.5K -300 -0.49% $55.00 61.1K Sep 20, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Options Exercise -$27K -876 -1.25% $30.86 69.1K Sep 20, 2022 Common Stock 70K $30.86 Direct F2
transaction PTCT Stock Option (Right to Buy) Options Exercise -$9.26K -300 -0.43% $30.86 68.8K Sep 20, 2022 Common Stock 69.1K $30.86 Direct F2
holding PTCT Stock Option (Right to Buy) 85.6K Sep 20, 2022 Common Stock 85.6K $51.00 Direct F2
holding PTCT Stock Option (Right to Buy) 72.5K Sep 20, 2022 Common Stock 72.5K $33.02 Direct F3
holding PTCT Stock Option (Right to Buy) 17.5K Sep 20, 2022 Common Stock 17.5K $33.02 Direct F4
holding PTCT Stock Option (Right to Buy) 59.5K Sep 20, 2022 Common Stock 59.5K $51.16 Direct F5
holding PTCT Stock Option (Right to Buy) 59.5K Sep 20, 2022 Common Stock 59.5K $66.49 Direct F6
holding PTCT Stock Option (Right to Buy) 54K Sep 20, 2022 Common Stock 54K $38.10 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021.
F2 Currently exercisable.
F3 This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
F4 This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
F5 This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
F6 This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.
F7 This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.